Navigation Links
PARI Pharma's Altera Delivers Gilead's Cayston in Head-to-Head Study With Tobramycin Inhalation Solution
Date:6/21/2010

MONTEREY, Calif., June 21 /PRNewswire/ -- In a head-to-head, Phase III clinical trial of Cayston delivered by the Altera Nebulizer System versus tobramycin inhalation solution in cystic fibrosis patients with Pseudomonas aeruginosa, the co-primary endpoint of non-inferiority for mean percent change in forced expiratory volume in one second (FEV(1)) percent predicted after 28 days of treatment was achieved.  Patients receiving Cayston had a mean increase in FEV(1) percent predicted from baseline to day 28 of 8.35 percent compared to 0.55 percent for patients receiving tobramycin inhalation solution, meeting the statistical definition of superiority for the Cayston and Altera combination.  Safety results were similar across both arms of the study, with lower incidence of cough in patients receiving Cayston.  This data was presented by Gilead Sciences during a late-breaker oral session on Friday at the 33rd European Cystic Fibrosis Conference (ECFC).  

In the study, 268 patients were randomized to receive Cayston or tobramycin inhalation solution over a 24-week treatment period.  Approximately 85 percent of patients in the study had received at least three courses of inhaled tobramycin in the 12 months prior to randomization.  Final six-month study results will become available for presentation later this year.

"We are very pleased to see these encouraging results.  Our goal is to improve therapies for respiratory care using our advanced aerosol delivery platforms, such as eFlow Technology.  In addition to aerosol delivery expertise, PARI Pharma also contributed to the initial formulation of Cayston and optimized the formulation to the Altera Nebulizer System.  As evidenced in multiple clinical trials, Altera delivers Cayston in two to three minutes – a significant reduction in delivery time compared to other inhalation therapies," said Martin Knoch, president of PARI Pharma GmbH.  "We are continuing to work with our pharmaceutical partners to create new drug-device combination therapies that give patients improved quality of life with shorter inhalation times."

Cayston is administered at a dose of 75 mg three times daily over a 28-day period and is delivered via the Altera Nebulizer System, a portable, drug-specific delivery device based on the eFlow Technology platform. Cayston was approved and the Altera Nebulizer System was cleared by the U.S. Food and Drug Administration (FDA) in February 2010.  Cayston received conditional marketing authorizations in the European Union and Canada in September 2009 and was approved in Australia in January 2010.  For more information about Cayston, visit www.cayston.com or call 1-877-7CAYSTON.   For more information on the Phase III study, please visit www.gilead.com.

About the Altera Nebulizer System and eFlow Technology

Cayston is administered by inhalation using the Altera Nebulizer System, an inhalation delivery device optimized specifically for use with Cayston.  Cayston should only be administered with the Altera Nebulizer System.  Cayston should not be mixed with any other drugs in the Altera Nebulizer Handset. Altera Nebulizer Systems are consistent with the specifications of the customized eFlow Nebulizer System used exclusively in all Cayston clinical trials. Altera is a drug-specific nebulizer system and its Instructions for Use specify that it is only to be used with Cayston.  Altera is not an ultrasonic nebulizer and it is not a general purpose electronic aerosol generator nebulizer.  No medication other than Cayston should be used in the Altera Nebulizer System.

The Altera Nebulizer System uses eFlow Technology to enable aerosolization of medication via a vibrating, perforated membrane that has thousands of small holes to produce the aerosol mist.  The Altera Nebulizer System and eFlow Technology are proprietary to PARI Pharma. 

About Cystic Fibrosis (CF)

CF is a chronic, debilitating genetic disease.  A major characteristic of CF is production of abnormally thick, sticky mucus in the lungs, trapping bacteria and predisposing patients to lung infections, which continually damage their lungs.  Chronic respiratory tract infection with P. aeruginosa contributes to the decline in pulmonary function, which is often associated with morbidity and mortality among CF patients. Currently there is no known cure for CF, and the goal of CF therapy is to control symptoms and prevent further lung damage.

About PARI Pharma

PARI Pharma focuses on the development of aerosol delivery devices and comprehensive inhalation drug development to advance aerosol therapies where drug and device can be optimized together. Based on PARI's 100-year history working with aerosols, PARI Pharma develops treatments for pulmonary and nasal administration customized with advanced delivery platforms, such as eFlow (lower respiratory) and Vibrent (upper respiratory) Technologies. PARI Pharma partners with pharmaceutical companies to develop new or improved therapies. PARI Pharma has several clinical development programs ongoing, either partnered or on its own, for cystic fibrosis, asthma, COPD, respiratory syncytial virus (RSV) infection, and treatments for lung transplant patients among other indications. PARI Pharma, a PARI Medical Holding company, is located near Munich, Germany with a major presence in the United States. Online at www.paripharma.com


'/>"/>
SOURCE PARI Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ePharmaSolutions Launches New Version of Electronic Monitor Visit Report Application With Industry-Leading Online and Offline Capabilities
2. Pharmasset to Present at the 28th Annual JPMorgan Healthcare Conference
3. Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
4. Pharmasset Reports Fiscal Year End 2009 Financial Results
5. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
6. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
7. Sosei Assigns AD 923 Assets to Pharmasol
8. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
9. Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
10. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
11. ePharmaSolutions Clinical Trial Investigator Portal Wins Bio-IT World 2009 Best Practice Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... N.Y. , May 22, 2017  Lilac ... treatment Gene-Eden-VIR/Novirin, announces the launch of a ... English, the results of a clinical study that ... year treatment with Gene-Eden-VIR/Novirin in individuals suffering from ... to note that there are no other treatments ...
(Date:5/15/2017)... , May 15, 2017  Amy Baxter MD, ... industry leader in noninvasive pain relief, was awarded a ... magazine. Baxter was recognized at the MM&M Top ... New York City on May 10, 2017. ... the biopharma industry go "beyond the pill."  ...
(Date:5/10/2017)... May 10, 2017 Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended April 1, 2017 ... $1.84 increased 666.7% compared to the prior year period ... in a significant gain, while non-GAAP diluted EPS of ... or 3.8% in constant currency terms.  Excluding the effects ...
Breaking Medicine Technology:
(Date:5/27/2017)... ... 27, 2017 , ... From May 21-23, hearing healthcare professionals gained a competitive ... at the Marriott Syracuse Downtown Hotel in Syracuse, New York. , As EarQ’s ... hearing healthcare providers to help them stay ahead in the industry. At the event, ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from biotech, ... 30th and 31st at The Four Seasons Hotel Boston. , The Boston ... sciences, offering exclusive access to key decision makers who influence deal making and ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of ... the healthiest seniors are located in the Midwest. With the average cost of healthcare ... people are concerned with both the quality and affordability of where they live. An ...
(Date:5/26/2017)... ... ... After raising nearly $30,000 on Kickstarter , about three-times its original ... discounted crowdfunding price on Indiegogo . , “Along with creating an anti-stress gadget ... a fidget toy to the market that was made of superior quality and wouldn’t ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled ... a new, informational blog post on insurance options. If a Bay Area patient has ... help save time and money. Visiting an in-network provider for a second opinion can ...
Breaking Medicine News(10 mins):